ReviewHaematologica2020
Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding.
Review in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Review
- Age-associated hematopoietic variants in the rhesus macaque.Blood advances · 2026Article
- Sex-Related Differences in On-Treatment Platelet Reactivity in Patients with Acute Coronary Syndrome.Biomedicines · 2025Article
- Clonal Hematopoiesis of Indeterminate Potential and Atrial Fibrillation: Insights into Pathophysiology and Clinical Implications.International journal of molecular sciences · 2025Review
- Unravelling the role of TET2 in venous thromboembolism: insights into mechanisms and therapeutic implications.Frontiers in cardiovascular medicine · 2025Review
- Demographic diversity in platelet function and response to antiplatelet therapy.Trends in pharmacological sciences · 2025Review
- Etiology and clinical course of severe and extreme thrombocytosis in children: a retrospective single-center study.European journal of pediatrics · 2024Article
- COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.Cell communication and signaling : CCS · 2024Review
- Thrombosis in Myeloid Malignancies: From CHIP to AML.Cardiovascular & hematological disorders drug targets · 2024Review
- Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation.Blood advances · 2023Article
- Prediction of major bleeding events in 1381 patients with essential thrombocythemia.International journal of hematology · 2023Article
- Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression.Biomedicines · 2023Review
- Clonal hematopoiesis of indeterminate potential and cardiovascular disease.Translational research : the journal of laboratory and clinical medicine · 2023Review
- Clinical Implication of DNMT3A and TET2 Genes Mutations in Cytogenetically Normal Acute Myeloid Leukemia.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- A case of ischemic stroke with hemorrhagic transformation associated with essential thrombocythemia and JAK-2 V617F mutation.BMC neurology · 2022Article
- Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.Blood advances · 2022Article
- Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk.Thrombosis and haemostasis · 2022Review
- Toward platelet transcriptomics in cancer diagnosis, prognosis and therapy.British journal of cancer · 2022Review
- Screening of potential hub genes in pulmonary thromboembolism.Experimental and therapeutic medicine · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelets are key elements in thrombosis, particularly in atherosclerosis-associated arterial thrombosis (atherothrombosis), and hemostasis. Megakaryocytes in the bone marrow, differentiated from hematopoietic stem cells are generally considered as a uniform source of platelets. However, recent insights into the causes of malignancies, including essential thrombocytosis, indicate that not only inherited but also somatic mutations in hematopoietic cells are linked to quantitative or qualitative platelet abnormalities. In particular cases, these form the basis of thrombo-hemorrhagic complications regularly observed in patient groups. This has led to the concept of clonal hematopoiesis of indeterminate potential (CHIP), defined as somatic mutations caused by clonal expansion of mutant hematopoietic cells without evident disease. This concept also provides clues regarding the importance of platelet function in relation to cardiovascular disease. In this summative review, we present an overview of genes associated with clonal hematopoiesis and altered platelet production and/or functionality, like mutations in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.